Idenix Pharmaceuticals, Inc. Intends To Appeal Norway District Court Decision Regarding Patent Invalidity Case

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., March 24, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it intends to file an appeal to challenge the Oslo, Norway District Court's (the "Court") decision in a patent invalidity case concerning Idenix's co-owned Norwegian patent NO 330 755 that covers certain 2'-methyl-2'-fluoro nucleoside compounds useful in the treatment of the hepatitis C virus (HCV) and other flaviviridae infections.

Help employers find you! Check out all the jobs and post your resume.

Back to news